Uveal Melanoma Clinical Trial
Official title:
Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma
Tumor Treating Fields targeted to liver metastases may improve outcomes for patients with metastatic uveal melanoma treated with immune checkpoint inhibitors.
Uveal melanoma is the most common ocular malignancy for adults and despite effective therapies, roughly 50% of patients will develop metastatic disease. Currently there is no therapy to improve the prognosis of patients with metastatic disease and these patients are usually treated with regimens used for cutaneous melanoma. Tumor Treating Fields is a new type of anti-cancer therapy approved by the FDA for use in glioblastoma multiforme and mesothelioma. TTF has been shown to activate the STING pathway leading to increased levels of dendritic cells in regional lymph nodes. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04364230 -
Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)
|
Phase 1/Phase 2 | |
| Completed |
NCT03652077 -
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
|
Phase 1 | |
| Active, not recruiting |
NCT05542342 -
Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases.
|
Phase 2 | |
| Completed |
NCT02849145 -
Evaluation Interest of the Circulating Tumor DNA Dosage in Patient With Hepatic Metastatic Uveal Melanoma Candidate to Complete Resection (ct DNA R0)
|
N/A | |
| Recruiting |
NCT01438658 -
Assessing the Clinical Effectiveness of Serum Biomarkers in the Diagnosis of Metastatic Uveal Melanoma
|
N/A | |
| Not yet recruiting |
NCT00811200 -
Treatment Of Radiation Retinopathy Trial
|
Phase 2/Phase 3 | |
| Completed |
NCT00121225 -
Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma
|
Phase 2 | |
| Recruiting |
NCT05077280 -
A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma
|
Phase 2 | |
| Completed |
NCT03297424 -
A Study of PLX2853 in Advanced Malignancies.
|
Phase 1 | |
| Withdrawn |
NCT05482074 -
Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2
|
Phase 2 | |
| Completed |
NCT04551352 -
A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas
|
Phase 1 | |
| Not yet recruiting |
NCT06246149 -
Adjuvant Tebentafusp in High Risk Ocular Melanoma
|
Phase 3 | |
| Completed |
NCT01955941 -
Vascular Response to Brachytherapy Using Functional OCT
|
||
| Completed |
NCT00661622 -
Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF
|
Phase 2 | |
| Recruiting |
NCT05502900 -
Adjuvant Melatonin for Uveal Melanoma
|
Phase 3 | |
| Active, not recruiting |
NCT03070392 -
Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
|
Phase 2 | |
| Recruiting |
NCT06284512 -
Uveal Melanoma - Comparative Study
|
||
| Recruiting |
NCT05524935 -
Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
|
Phase 2 | |
| Active, not recruiting |
NCT02913417 -
Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06073548 -
Patient Experience and Quality of Life During the Surveillance Phase of Uveal Melanoma: A Prospective Multi-method Study
|